AUTHOR INDEX

(BR) = Book reviewer; (C) = commentary; (E) = editorial; (L) = letter to the editor; (S) = supplement.

Aalto, M., 1447
Adlaf, E.M., 1531
Ahern, J., 739
Ahlbom, A., 1453
Ahlner, J., 463
Ahluwalia, J.S., 1387
Airey, N., 179
Alfredsson, L., 1453
Ali, R., 413, 441
Allen, B.A., 895
Andersen, A., 1505
Andersen, A.T., 355
Andersen, M.R., 585, 598
Anderson, L.M., 1537
Anderson, P., 1327 (BR), 1354
Anderson, T.L., 761
Anthony, J.C., 71
Asbridge, M., 1531
Aubin, H.-J., 1575
Augustin, R., 471
Avenevoli, S., 1 (S1)
Aveyard, P., 345, 1315

Babor, T.F., 1 (E), 1341 (E)
Bachman, J.G., 225
Baker, A., 419
Baker, D., 1731
Balmford, J., 837
Bammer, G., 1605
Barrio, G., 749
Baumohl, J., 965
Béria, J.U., 799
Beautrais, A.L., 1681
Beck, O., 63 (S2), 463
Beirness, D., 1531
Bellis, M.A., 1713
Benigeri, M., 1585
Bennett, A., 1713
Bergler, R., 1774 (L)
Berglund, M., 627
Bergman, H., 1513
Berlin, I., 1575
Berridge, V., 1351
Bethlehem, J., 725
Biberman, R., 1403
Bigelow, G.E., 427
Bird, S.M., 185
Bischof, G., 1737
Bjarnason, T., 815
Black, M., 995
Blaszczynski, A., 733
Boca, F.K.D., 1 (S2)
Bolinder, G., 1201
Bond, C.M., 119
Bond, J., 1277
Boomsma, D.I., 923
Borges, G., 1277
Borland, R., 837
Borrey, D., 1427
Bosman, I., 987
Bovbjerg, D.H., 657
Boyarsky, Y., 657
Boyer, M., 61
Boys, A., 951
Bradley, B.P., 825, 1409
Brandt, L., 463
Bransberger, P., 617
Branting, M., 1453
Bravo, M.J., 749
Breen, R., 397
Breteler, M.H.M., 1143
Bricker, J.B., 585, 598
Bridgeman, K., 43
Briscoe, S., 1287
Britton, J., 1199
Brodeur, J.-M., 1585
Brown, W., 1419
Bruneau, J., 7
Burchell, A.N., 1257

Caetano, R., 791, 859 (BR)
Calderon, C., 1585
Calzavara, L.M., 1257
Caplehorn, J., 1633 (L)
Carlin, J.B., 685
Carnwath, T., 1464 (L)
Carrà, G., 1039
Carter, L., 867 (E), 873, 1775 (L)
Casswell, S., 601
Catley, D., 1387
Caulkins, J.P., 1177 (E)
Ceder, G., 463
Celentano, D.D., 1153
Chaloupka, F., 105 (S1)
Chaloupka, F.J., 147 (S1), 1363
Chand, P.K., 1635 (L)
Charland, L.C., 1634 (L)
Chassin, L., 595
Chavan, B.S., 1169 (L)
Chen, C.-Y., 71
Cheng, K.K., 345
Cheng, R., 23
Cherpitel, C.J., 1277
Christodoulou, G.N., 561
Clark, N., 1605
Clayton, R., 105 (S1)
Clayton, R.R., iii (S1)
Clerici, M., 1039
Coffey, C., 685
Coffin, P.O., 739
Collins, R.L., 1297
Compton, W.M., 635
Conigliaro, J., 547 (BR)
Conigrave, K.M., 31 (S2)
Connolly, G., 1547
Connors, G.J., 21 (S2)
Cook, B.L., 1547
Cook, C., 859 (BR)
Cook, P.J., 1356
Cook, T.D., 151 (S1)
Cooney, J.L., 913
Cooney, N.L., 913
Cooper, G., 995
Cooper, S.M., 225
Copley, N., 235
Cottler, L.B., 635
Courtwright, D., 1639 (BR)
Courtwright, D.T., 717
Croghan, E., 1315
Crosse, S., 617
Cumsille, P., 21 (S1)
Cunningham, J.K., 1229, 1463 (L)
Cunningham-Williams, R.M., 635
Currens, M., 453
Curtis, R., 159

Dale, L.C., 569
Danielsson, T., 1395
Danz, C., 441
Darke, S., 93, 199, 413, 711 (E), 1129, 1169 (L)
Darkes, J., 1 (S2)
Darling, N., 21 (S1)
Daum, I., 1521
David, A.S., 1731
Davidaviciene, A.G., 815
Davies, P., 31 (S2)
Davis, P., 253 (E), 1471 (E)
Day, C., 93, 1641 (E)
De Houwer, J., 825
de la Fuente, L., 749
de Vries, H., 1755
DeFuentes-Merillas, L., 725
Degenhardt, L., 199, 387 (E), 685, 1169 (L), 1493
Delgado-Rodríguez, M., 611
Demers, A., 205
Dickerson, M., 53, 61, 709 (E)
Dillon, P., 199
Dinh, Q.T., 1239
Dolan, K., 93, 153
Domingo, L., 749
Donnelly, N., 1287
Dorsey, E., 1379
Doyle, K., 509
Duchateau, L., 1427
Due, P., 1505

Ebbert, J.O., 569
Ebersole-Robinson, M., 1387
Eder, H., 103
Edwards, B.Q., 1077
Edwards, G., 130 (BR), 141 (E), 253 (E), 376 (BR), 547 (BR), 1027 (E), 1181, 1182, 1471 (E), 1645 (E), 1646 (E), 1784 (BR)
Eksborg, S., 463
Ellickson, P.L., 1297
Elliott, P., 419
Epstein, D.H., 269, 1322 (L)
Erblich, J., 657
Ertl, M., 693
Erwin, P.J., 569

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

Escobar, M., 1257
Etter, J.-F., 941

Fafouti, S., 561
Fagerström, K.O., 1191
Fagerström, K.P., 1204
Fagerstrom, K., 130 (BR)
Falba, T., 847
Farran, J.C., 1782 (BR)
Felsch, J.A., 1239
Fendrich, M., 1693, 1705
Fergusson, D.M., 1681
Ferrence, R., 720
Fertig, J., iii (S2)
Field, M., 825
Fiellin, D.A., 385 (E)
Finney, J., 533 (L)
Finney, J.W., 1638 (BR)
Fischer, G., 103
Flaherty, B.P., 1077
Flay, B., iii (S1), 79 (S1)
Flom, P.L., 159
Ford, P., 111
Fox, H., 1003 (L)
Foxcroft, D.R., 397
Freeman, K., 83
French, M.T., 1647
Friedman, S.R., 159
Friedmann, P.D., 673
Frischer, M., 471
Fry, C.L., 171
Fugelstad, A., 463

Gaigi, H., 1585
Galanti, M.R., 1183, 1205
Galea, S., 739
Gandhi, D.H., 453
Gannon, M., 1615
Gefen, L., 255
Gehrman, C., 1239
George, T.P., 1625
Gerada, C., 785
Gerber, Y., 1403
Gerstein, D., 719
Gerstein, D.R., 673, 1661, 1678
Ghazi, A., 933
Giacomuzzi, S.M., 693
Giesbrecht, N., 1277, 1328 (BR)
Gillison, F., 1563
Gilljam, H., 1183, 1205
Giovino, G., 79 (S1)
Gmel, G., 1209, 1433
Gómez-Ortega, A., 611
Göransson, M., 1513
Godtfredsen, N.S., 355
Gonsai, K., 1625
Gonzalez, G., 1625
Goos, C., 378 (BR)
Gorgels, W.J.M.J., 1143
Gossop, M., 291
Graham, H., 1765
Graham, K., 33, 1021 (E), 1209
Gray, S.F., 1163
Greenfield, T.K., 517
Greenough, A., 785
Griffin, C., 345
Grønbæk, M., 355
Guagliardo, V., 1249
Guichard, A., 1585

Haber, P., 31 (S2)
Hajak, G., 1371
Hajek, P., 1563
Hall, W., 93, 867 (E), 873, 1493, 1775 (L)
Hallqvis, J., 1453
Hammar, N., 1453
Hapke, U., 805, 1101, 1737
Harford, T.C., 559 (E), 1483 (E)
Hauge, R., 717
Haw, J., 131 (BR)
Hay, M.M.A., 933
Hayes, M., 453
Heather, N., 1025 (E)
Heeb, G.G.J.L., 1774 (L)
Heeb, J.-L., 1433
Heilig, M., 1513
Heishman, S.J., 1537
Helander, A., 63 (S2)
Heloma, A., 1111
Henry, J., 419
Henry, J.A., 365
Hickman, M., 419
Hill, D.J., 1087
Hinterhuber, H., 693
Ho, S.Y., 215
Hodgson, R.J., 43
Holder, H., 865 (E)
Holstein, B.E., 1505
Hooper, R., 601
Hopper, J.L., 1087
Horn, P.S., 317
Horton, N.J., 509
Horwood, L.J., 1681
Hovell, M.F., 1239
Hsieh, C.-M., 965
Hu, H.-C., 1723
Huang, J.-S., 1723
Hubbell, A., 1693
Hughes, J.R., 1747
Hughes, K., 1713
Hulse, G.K., 1061
Humeniuk, R., 413
Humphreys, K., 1362
Hunter, E., 1731
Hutchinson, S.J., 185
Huyser, D.J., 1379

Indig, D., 97
Ireland, D., 397
Iversen, L., 1505

Jäntti, M., 365
Jaakkola, M.S., 1111
Jacobson, P.D., 123 (S1)
Jaffe, J.H., 453, 1781 (BR)
Janghorbani, M., 215
Janus, E.D., 215
Jarlais, D.C.D., 159
Jarvis, M.J., 597, 1569
Javors, M.A., 45 (S2)
Jay, J., 995
Jefferis, B., 1765
Jensen, M.K., 355
Jernigan, D., 1360
Jhingan, H.P., 339
John, U., 805, 1101, 1737
Johnson, B.A., 45 (S2)
Johnson, K., 785
Johnson, T.P., 1693, 1705
Johnsson, K.O., 627
Johnston, L.D., 225
Jones, B.C., 235, 1069
Jones, B.T., 235, 1069
Jones, C., 83
Jorm, L., 97

Kairouz, S., 205
Kaskutas, L.A., 901
Kassem, H., 933
Katholi, C., 536 (L)
Katholi, M., 536 (L)
Katholi, R., 536 (L)
Katzir, I., 1403
Kavanagh, G.J., 453
Kawichai, S., 1153
Kayemba-Kay's, S., 1599
Kealey, K.A., 585, 598
Keen, J., 191
Keithly, L., 1547
Kelleher, M., 546 (BR)
Kelly, J.F., 499
Kemmler, G., 693
Kendell, R., 143
Kenkel, D., 1307
Khamis, T.A., 933
Khandelwal, S.K., 339
Kidd, T., 291
Kikuchi, A., 771
Kim, S., 317
Kirch, W., 1371
Kleiman, M., 871, 1640 (BR)
Kobus, K., 37 (S1)
Koeter, M.W.J., 725
Kolly, S., 1167
Kosten, T., 665
Kosten, T.R., 1625
Kottiri, B.J., 159
Kozlowski, L.T., 1077
Kranzler, H.R., 617, 913
Kraus, L., 471
Kremers, S.P.J., 1755
Krenz, S., 1167
Kümmler, P., 471
Kuo, M., 1433
Kurz, M., 693
Kutin, J.J., 1605

Laclyde, J.P., 1599
Ladouceur, R., 733
Lam, T.H., 215
Lambert, W., 1427

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

Lamble, R., 1531
Lancrenon, S., 1575
Landfeldt, B., 941, 1395
Langendam, M.W., 987
Langer, M., 103
Larson, M.J., 509
Lascaratos, J., 561
Lavoie, M.E., 733
Lawrence, E., 1731
Lawrence, T., 345, 1315
le Houezec, J., 941
Leenheer, A.P.D.E., 1427
Leifman, A., 1453
Lemmens, P.H., 247 (E)
Leon, A.C., 739
Leri, F., 7
Leroux, B.G., 585, 598
Lert, F., 1585
Levy, J.A., 761
Lewis, J., 1137
Li, M.D., 23
Li, S.-M., 1723
Liang, L., 105 (S1)
Liappas, J.A., 561
Lillard, D.R., 1307
Lintzeris, N., 171, 385 (E), 1605
Lister-Sharp, D.J., 397
Litten, R.Z., iii (S2)
Liu, L.-M., 1229, 1463 (L)
Livingston, P., 837
Lloyd, D.A., 305
Longabaugh, R., 535 (L)
Lowe, G., 397
Lynskey, M., 1129, 1493
Lynskey, M.T., 685

Mäkelä, P., 1353
Ma, J.Z., 23
MacDonald, F., 977, 1615
Macdonald, S., 1277
Maciejewski, P.K., 847
Madden, P., 419
Maes, R.A.A., 987
Magnusson, Å., 1513
Maguet, O., 1585
Maisto, S.A., 21 (S2)
Major, C., 1257
Makkai, T., 83
Mann, K., 1352
Mann, K.F., 857 (BR)
Mann, R.E., 1531
Manor, O., 1765
Marek, P.M., 585, 598
Marino, M.E.D., 1747
Mariscal-Ortiz, M., 611
Mark, T.L., 617
Marques, P.R., 13 (S2)
Marriott, J., 179
Marsden, J., 291, 951
Matheson, C., 119
Mathios, A., 1307
Matt, G.E., 1239
Mattick, R.P., 387 (E), 441, 1004 (L), 1137, 1169 (L)
Matzger, H., 901
Mayo, M.S., 1387
Mazure, C.M., 847
McBride, A.J., 487
McCaffrey, D., 1297
McCollister, K.E., 1647
McEwen, A., 523
McGowan, C., 487
McGrath, C., 791
McGregor, C., 413
McIntosh, J., 977, 1615
McKee, S.A., 847
McKeganey, N., 977, 1615
McKellar, J.D., 499
McNary, S., 453
McRobbie, H., 1563
Medford, N., 1731
Mendoza-Sassi, R.A., 799
Merikangas, K.R., 1 (S1)
Meyer, C., 805, 1101, 1737
Meyer, E., 1427
Meyer, R.E., 1465
Midanik, L.T., 517
Mignon, P., 1249
Milani, R.M., 1003 (L)
Miller, P., 815
Miller, W.R., 5 (C)
Millson, M., 1257
Mogg, K., 825, 1409
Mol, A.J.J., 1143
Monteiro, M., 1209
Montori, V.M., 569
Moos, B.S., 325
Moos, R., 499
Moos, R.H., 325
Morley, K., 1775 (L)
Morley, K.I., 867 (E), 873
Mott, J., 1171 (L)
Müller, W.E., 1371
Murthy, P., 1635 (L)
Musharrafieh, U., 933
Myers, T., 1257

Neaigus, A., 159
Neale, J., 1171 (L)
Nemtsov, A., 369 (L), 1364
Neumann, R., 1403
Neumann, T., 81 (S2)
Niaura, R., 657, 1575
Nichter, M., 79 (S1), 105 (S1), 139 (S1)
Nieminen, R., 365
Nixon, L.N., 1321 (L)
Nociar, A., 815
Norfolk, G.A., 1163

Öjesjö, L., 545 (BR)
O'Brien, S., 441
O'Connor, J., 53
O'Connor, K., 733
O'Connor, R.J., 1077
O'Malley, P.M., 225
Obadia, Y., 1249
Ojanperä, I., 365
Okuyemi, K.S., 1387
Oliver, J., 995
Oliver, P., 191
Oliveto, A., 665, 1625
Oncken, C.A., 913
Orford, J., 1675 (C)
Ortner, R., 103
Owen, N., 837
Owen, T., 97

Palma-Pérez, S., 611
Panjari, M., 1605
Parrott, A.C., 1003 (L)
Parry, C.D.H., 1365
Pates, R., 487
Patton, G., 685
Pavlakis, A., 815
Pedarriosse, A.-M., 1575
Pekuri, P., 1447
Peretti-Watel, P., 1249
Perngmark, P., 1153
Peterson, A.V., Jr, 585, 598
Petry, N.M., 645, 1674
Phillips, M.L., 1731
Pilkey, D.T., 913
Piper, J., 1069
Pitcairn, J., 119
Pittrow, D., 1371
Pledger, M., 601
Poling, J., 665, 1625
Pollack, H.A., 123 (S1)
Poole, V.H., 617
Power, C., 1765
Prasad, K.M.R., 339
Presson, C.C., 595
Preston, K.L., 269, 1322 (L)
Pruvost, J., 1249

Quinn, T., 159

Raj, L., 1169 (L)
Rajs, J., 463
Ramadan, R., 487
Rames, A., 1575
Ramisetty-Mikler, S., 791
Ramstedt, M., 1267
Ramström, L., 1198
Rankin, C., 536 (L)
Rehm, J., 534 (L), 1008 (BR), 1209, 1433, 1774 (L)
Resnicow, K., 1387
Reuter, P., 718, 1177 (E)
Richard, L., 1585
Richardson, J., 1705
Richmond, R., 553 (E)
Ridenour, T.A., 635
Riemer, Y., 693
Ritter, A.J., 1605
Rössler, H., 693
Robins, L., 1010 (BR)
Robins, L.N., 1053
Rohrmeister, K., 103
Romanus, G., 1366
Romelsjö, A., 1453
Room, R., 713, 721, 1209

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

Rosenthal, R.J., 1674
Ross, J., 1129
Rotrosen, J., 317
Rouen, D., 93
Rowland, L.C., 569
Royuela, L., 749
Rumpf, H.-J., 805, 1101, 1737
Rush, B.R., 895, 1119
Russell, A., 1419
Rutter, S., 153
Ryan, M., 119
Rydberg, U., 1513

Sørensen, T.I.A., 355
Saitz, R., 509
Salmon, A., 97
Samet, J.H., 509
Sandoval, M., 159
Sarason, I.G., 585, 598
Savolainen, T., 365
Savva, S., 3 (E), 253 (E), 1471 (E)
Schell, T., 1297
Schildt, E.-B., 1191, 1204
Schindler, S.D., 103
Schippers, G.M., 725
Schlebusch, P., 1521
Schlossberg, J., 1257
Schulenberg, J.E., 225
Schumann, A., 1101
Sévigny, S., 733
Segan, C., 837
Segura, L., 1782 (BR)
Seijas, D., 132 (BR)
Seivewright, N., 251 (E)
Sempos, C.T., 1209
Seppä, K., 1447
Sevarino, K., 1625
Seymour, A., 995
Sharma, A., 339
Shearer, J., 1137
Shepherd, J.P., 43
Sherman, S.J., 595
Shiffman, S., 1409, 1747
Shyangwa, P., 339
Sierra, M., 1731
Sillero-Arenas, M., 611
Silva, T., 749
Simon, N., 1004 (L)
Singal, B., 317
Singleton, E.G., 1537, 1575
Skinner, W., 1329 (BR)
Skipper, G.E., 51 (S2)
Skog, O.-J., 883
Slobodyan, S., 1053
Smart, R.G., 1531
Smith, A.J., 43
Smith, H., 235
Smith, I., 1464 (L)
Smolka, M., 857 (BR)
Sofuoglu, M., 1625
Soldz, S., 1379
Soletti, J., 1585
Somoza, E.C., 317
Song, X., 617
Spies, C., 81 (S2)
Spitznagel, E.L., 635
Spring, B., 657
Sstormer, E., 536 (L)
Stenius, K., 3 (E)
Steptoe, A., 523
Stergar, E., 815
Stericker, P., 536 (L)
Stewart, D., 291
Stewart, J., 7
Stimson, G., 419
Stockwell, T., 1009 (BR), 1358
Stʳduto, G., 1531
Strain, E.C., 427
Strike, C., 1257
Swan, G.E., 23, 596
Swartz, J.A., 965
Sweanor, D., 1197
Sweeney, C.T., 1747
Swift, R., 73 (S2)

Tønnesen, P., 1395
Tait, R.J., 1061
Tamim, H., 933
Tardiff, K., 739
Taylor, A., 523
Teesson, M., 379 (BR), 1129
Terro, A., 933
Thackway, S., 97
Thom, B., 375 (BR)
Thomas, A.P., 1069
Thomson, R., 1713
Thorsen, T., 355
Tippetts, A.S., 13 (S2)
Törrönen, J., 281
Tober, G., 860 (BR)
Toce-Gerstein, M., 1661, 1678
Tolstrup, J.S., 355
Toomey, T.L., 1357
Topp, L., 93, 1641 (E)
Totté, M., 987
Trenckmann, U., 1521
Tsiboukli, A., 1010 (BR)
Turingan, M.R., 1239
Turner, C., 1419
Turner, R.J., 305

Uchtenhagen, A., 1330 (BR)
Uekermann, J., 1521
Uhl, A., 471
Uhl, G.R., 872
Urbanoski, K.A., 895
Ussher, M., 523

Värre, T., 1447
Vaillant, G.E., 1043
van Ameijden, E.J.C., 987
van Balkom, A.J.L.M., 1143
van Beek, I., 1137
van de Lisdonk, E.H., 1143
van der Ven, A.H.G.S., 1143
van Peteghem, C., 1427
van Teijlingen, E., 119
VanDenBrink, W., 725
Verger, P., 1249
Vickers, K.S., 569
Vingilis, E., 1531
Vink, J.M., 923
Vitória, P.D., 1755
Vlahov, D., 739
Voas, R.B., 13 (S2), 1359
Volberg, R.A., 1661, 1678
Voshaar, R.C.O., 1143
Vuori, E., 365

Wada, K., 771
Wagenaar, A.C., 1357
Wahlsten, P., 365
Wakefield, J., 419
Wakefield, M., 79 (S1)
Wallace, C., 419
Wallace, E., 1257
Wallace, J.M., Jr, 225
Walsh, S.L., 427
Waraich, B.K., 1169 (L)
Warner, J., 139 (E), 858 (BR)
Waters, A.J., 1409
Wayne, G.F., 1547
Wearing, A.J., 1087
Weatherburn, D., 83
Weinmann, W., 51 (S2)
Weir, C., 995
Weisner, C., 901
Weiss, S., 255
Wells, S., 33
Welp, E.A.E., 987
Wennike, P., 1395
West, R., 523
Westin, Å., 1395
Wetzels, J.J.L., 1755
White, J.M., 441
White, V.M., 1087
White, W.L., 261
Whitfield, J.B., 31 (S2)
Wiebel, B., 1521
Wiessing, L., 471
Wig, N.N., 377 (BR)
Wilcox, P., 57 (S1)
Wild, T.C., 1119
Willemsen, G., 923
Winhusen, T.M., 317
Winter, M., 509
Wirtz, P.W., 535 (L)
Wislar, J.S., 1693
Wittchen, H.U., 1371
Wodak, A., 1137
Wodak, A.D., 153
Wolff, K., 1639 (BR)
Wolk, S., 441
Woody, G., 132 (BR)
Wurst, F.M., 51 (S2)

Ye, Y., 1277
Yu, S.R.-L., 1723

Zenilman, J., 159
Zhang, Z., 673
Zimmermann, G., 1167
Zitman, F.G., 1143
Zullino, D.F., 1167
Zunzunegui, M.-V., 1585
Zurbrügg, C., 1433

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

SUBJECT INDEX

(BR) = Book review; (C) = commentary; (E) = editorial; (I) = interview; (L) = letter to the editor; (N & N) = news and notes; (O) = obituary; (S) = supplement.

Abstinence, treatment outcomes, alcohol dependence, 901–911
ACS *see* Amsterdam Cohort Studies
Addict, marketing, 136 (N & N), 550 (N & N)
Addiction, 861 (N & N), 1471–1481 (E)
Addiction, 1327 (BR)
  behavioral techniques, management, 378–379 (BR)
  cost–benefit analyses, economic evaluations, interventions, 1647–1659
  cures, USA, medicinal specifics, 261–267
  development, recovery, 1783–1784 (BR)
  ethics, neuroscience, 867–870 (E), 871–874 (C)
  gambling, theory, 709 (E)
  management, behavioral techniques, 378–379 (BR)
  master class, research, 383–284 (N & N)
  modernity, 1329–1330
  neuroscience, ethics, 867–870 (E), 871–874 (C)
  opiates, 1638–1639 (BR)
  recovery, development, 1783–1784 (BR)
  researcher, vacation habits, 245 (N & N)
  treatment, 858–859 (BR)
Addictive behavior
  attentional bias, automaticity, gambling, 61–70
  drugs, 857 (BR)
Addictive states, 1465–1466 (BR)
Administration route, heroin, HIV, 749–760
Administrative license suspension law, 1531–1536
Advertising
  alcohol, youths, awareness, 1297–1306
  Europe, tobacco, 383 (N & N)
Aging, marginality, injecting drug use, 761–770
Aggression, alcohol, drinking patterns, social context, 33–42
Alcohol
  abstinence, treatment outcomes, dependence, 901–911
  advertising awareness, youths, 1297–1306
  aggression, drinking patterns, social context, 33–42
  Alexander the Great, 561–567
  AUDIT, use disorders, prevalence, 799–804
CAGE questionnaire, 339–343
Canada, liver cirrhosis, 1267–1276
cognitive functioning, depression, 1521–1529
consumption
  drinking patterns
    Hong Kong, 215–224
    Québec, 205–213
  Russia, 369–370 (L)
control, Finland, 1173–1174 (BR)
dependence
  abstinence, treatment outcomes, 901–911
  mortality, 1043–1051
  natural recovery, 1727–1746
  relapse, 706–707 (N & N)
  treatment outcomes
    abstinence, 901–911
developing societies, 1008–1009
drinking patterns
  Europe, 1007–1008 (BR)
  gender, myocardial infarction, 1453–1468
  injury, 1782–1783 (BR)
  risk, 1209–1228
driving, prevention, 1777–1778 (N & N)
drugs
  dependence, substance misuse, 635–644
  research, 1641–1643 (E)
drug-related deaths, opiates, cocaine, 739–747
elderly people, 546–547 (BR)
general surgery, mortality, 611–616
intervention, 1025–1026
  injury, 43–52
  mental health disorders, 1061–1068
  primary care, 1447–1451
long-term influence, treatment outcomes, 325–337
mental health disorders, intervention, 1061–1068
Nordic, research, 245–246 (N & N)
opiates, cocaine, drug-related deaths, 739–747
policy research, 1341 (E)
research
  drugs, 1641–1643 (E)
  industry, 1773–1774 (L)
  Nordic, 245–246 (N & N)
social use, cannabis, attentional bias, 235–244
treatment, 1335 (N & N), 1637–1638 (BR)
treatment outcomes
  abstinence, dependence, 901–911
  long-term influence, use disorders, 325–337
Alcohol Education and Research Council, UK, 862 (N & N)
Alexander the Great, 561–567
Amsterdam Cohort Studies, HIV/AIDS, 246 (N & N)
Areca quid, 1723–1729
Arousal, expectancy, video lottery, gambling, 733–738
ASE model *see* Attitudes–Social Influence Self-efficacy model
Attentional bias
  addictive behavior, automaticity, gambling, 61–70
  alcohol, cannabis, social use, 235–244
  cannabis, social use, alcohol, 235–244
  craving, smoking, 1409–1417
  eye movements, smoking, 825–836
Attitudes, prisons, substance misuse, 179–184
Attitudes–Social Influence Self-efficacy model, 1723–1729
AUDIT, 799–804
Audit, treatment facilities, 1467 (N & N)
Australia
  gamma-hydroxybutyrate, overdose, 199–204
  methadone, 385–386 (E)
Authors, editors, ethics, 1–2 (E)
Award, young researchers, 1778 (N & N)

Behavioral techniques, 378–379 (BR)
Benzodiazepine
  craving, questionnaire development, 1143–1152
  prevalence, prisons, 1427–1432
Biological markers
  clinical practice, drinking patterns, 81–91 (S2)
  drinking patterns, 45–50 (S2)
    clinical practice, 81–91 (S2)
    ethyl glucuronide, 51–61 (S2)
    5-hydroxytryptophol, 63–72 (S2)
    liver function tests, 31–43 (S2)
Black market, USA, 1639 (BR)
Blood-borne virus, injecting drug use, 171–178
Borkenstein, Robert F., 371–372 (O)
Breath alcohol concentration, ignition interlock, 13–19 (S2)
Broken needles, 1163–1166
Buprenorphine
  conception, pregnancy, 103–110
Bupropion, menthol, smoking, ethnicity, 1387–1393

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

Caffeine, children, 536–537 (L)
CAGE questionnaire, Nepal, 339–343
Canada
  alcohol, mortality, 1267–1276
  cannabis, 383 (N & N), 1335 (N & N)
  drinking patterns
    alcohol, mortality, liver cirrhosis, 1267–1276
    injury, 865–866 (E)
      mortality, 883–893
Cannabis, 1014 (N & N)
  League of Nations, international control, 143–151
CARG *see* Clinical Addictions Research Group
Causal chain analysis, 533–534, 534–535, 535–536 (L)
Central Europe, drug demand, 377–378 (BR)
Cessation
  children, smoking, parents, 585–593, 595–599 (C)
    transtheoretical model, 345–354, 837–846
Chewing tobacco, spit tobacco, systematic review, 569–583
Children
  caffeine, 536–537 (L)
  cessation, parents, smoking, 585–593, 595–599 (C)
  drug education, 977–986
  drugs, exposure, 1615–1623
Cigar use, youths, drug delivery device, 1379–1386
Cigarettes
  design, needs-based targeting, 1547–1561
  prices, 105–122 (S1), 147–149 (S1)
Clinical Addictions Research Group, Scotland, 1014–1015 (N & N)
Clinical practice
  biomedical markers, drinking patterns, 81–91 (S2)
  substance misuse, 545–546 (BR)
Clinical trial, sweat patches, cocaine, 317–324
Clonidine, 427–439
Clubs, drugs, 1693–1703
Cocaine
  clinical trial, sweat patches, 317–324
  crack, neighborhood, ethnicity, 1705–1711
  dependence, treatment, dexamphetamine, 1137–1141
  dexamphetamine, dependence, treatment, 1137–1141
Cognitive functioning, alcohol, depression, 1521–1529
Collaborative approach, families, 5–6 (C)
Collaterals, self-report, drinking patterns, 21–29 (S2)
College of Addictions, Europe, 862 (N & N)
Community
  drug use, sexually transmitted infections, 159–169
  smoking, youths, 57–77 (S1)
Conception, abstinence syndrome, buprenorphine, 103–110
Consent
  heroin, 1775–1776
    therapy, 1634–1635 (L)
Constipation, smoking, cessation, 1563–1567
Contingency management, 665–671
Control
  alcohol, Finland, 1173–1174 (BR)
  tobacco, 137 (N & N)
Cook, Timothy, 1029–1038 (I)
Cost–benefit analyses, 1647–1659
Crack, neighborhood, ethnicity, 1705–1711
Craving
  attentional bias, smoking, 1409–1417
  benzodiazepine, questionnaire development, 1143–1152
  family history, smoking, 657–664
  reliability, smoking, 1537–1546
Credit card breathalyser, 550 (N & N)
Crime, drugs, 1010
Criminal justice system, 1119–1128
Culture, 139–145 (S1)
Current drinkers, prevalence, alcohol survey, 517–522

Damage, smoking, tobacco, 129–130 (BR)
Death, MDMA, 365–368
Delphi study, drug use, 487–497
Depersonalization, drug use, 1731–1736
Depression
  alcohol, cognitive functioning, 1521–1529
  cannabis, 1493–1504
Deterrence, administrative license suspension law, 1531–1536
Detoxification
  buprenorphine, heroin, treatment outcomes, 453–462
  primary care, 509–516
Developing societies, alcohol, 1008–1009
Dexamphetamine, cocaine dependence, treatment, 1137–1141
Diagnosis
  impulse control disorders, gambling, 1661–1672, 1673–1679 (C)
Disability, drug use, payees, 965–975
Drinking patterns
  aggression, alcohol, social context, 33–42
  alcohol
    consumption
      Hong Kong, 215–224
      Québec, 205–213
    Canada, mortality, liver cirrhosis, 1267–1276
    dependence, self-report, iii–iv (S2)
    Europe, 1007–1008 (BR)
    gender, myocardial infarction, 1453–1468
    injury, 1782–1783 (BR)
      risk, 1209–1228
    liver cirrhosis, Canada, mortality, 1267–1276
    physician's inquiries, use, 895–900
    Québec, consumption, 205–213
    self-report, dependence, iii–iv (S2)
    Switzerland, 1433–1446, 1774–1775 (L)
biological markers, 45–50 (S2)
  ethyl glucuronide, 51–61 (S2)
  5-hydroxytryptophol, 63–72 (S2)
  liver function tests, 31–43 (S2)
biomedical markers, clinical practice, 81–91 (S2)
breath alcohol concentration, ignition interlock, 13–19 (S2)
Canada
  alcohol, mortality, liver cirrhosis, 1267–1276
  injury, 865–866 (E)
    mortality, 883–893
collaterals, self-report, 21–29 (S2)
Europe, alcohol, 1007–1008 (BR)
expectancy, gender, 1069–1075
fetal alcohol syndrome, 1513–1520
gender
  alcohol, myocardial infarction, 1453–1468
  sexual behavior, expectancy, 1069–1075
Hong Kong, alcohol consumption, 215–224
ignition interlock, breath alcohol concentration, 13–19 (S2)
injury, 1483–1484 (E)
intimate partner violence, USA, 791–797
liver cirrhosis, Canada, 1267–1276
liver function tests, biological markers, 31–43 (S2)
mortality
  alcohol, liver cirrhosis, Canada, 1267–1276
myocardial infarction, 1453–1468
physician's inquiries, alcohol use, 895–900
pregnancy, fetal alcohol syndrome, 1513–1520
risk, alcohol, injury, 1209–1228
self-report
  alcohol dependence, iii–iv (S2)
  collaterals, 21–29 (S2)
  validity, 1–12 (S2)
socioeconomic status, 559 (E)
  youths, 601–610
Switzerland, alcohol, 1433–1446, 1774–1775 (L)

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

USA, intimate partner violence, 791–797
validity, self-report, 1–12 (S2)
youths, 1505–1511
socioeconomic status, 601–610
Driving
alcohol, prevention, 1777–1778 (N & N)
cannabis, 1778 (N & N)
Drug abuse, Spain, 861 (N & N)
Drug control, 717–723 (C)
USA, 375–376 (BR)
Drug demand, Central Europe, 377–378 (BR)
Drug dependence
alcohol dependence, substance misuse, 635–644
Egypt, 707 (N & N)
ethnicity, 305–315
substance misuse, alcohol dependence, 635–644
Drug education, children, 977–986
Drug policy, 1639–1640 (BR)
Drug use
community sample, sexually transmitted infections, 159–169
Delphi study, pharmacy, 487–497
depersonalization, derealization, 1731–1736
disability, welfare, payees, 965–975
European Union, Norway, 471–485
fuzzy set reliability, 1239–1247
hypnotic dependence, zolpidem, zopiclone, 1371–1378
improvement, treatment outcomes, 673–684
Norway, European Union, 471–485
payees, disability, welfare, 965–975
recreation, tourism, 1713–1721
retention, improvement, 673–684
sport, youths, 1249–1256
Drug-related deaths
alcohol, opiates, cocaine, 739–747
heroin
methadone, 387–388 (E), 419–425
morphine, 6-monoacetylmorphine, 463–470
heroin, 387–388 (E), 419–425
Scotland, 995–1002
release from prison, Scotland, 185–190
Scotland
methadone, 995–1002
6-monoacetylmorphine, heroin, morphine, 463–470
substance misuse, opiates, overdose, 191–197
Drugs
addictive behavior, 857 (BR)
children, exposure, 1615–1623
clubs, prevalence, risk, 1693–1703
crime, 1010
literature, 1784 (BR)
Dual diagnosis, substance misuse, psychiatric disorders, 131–132 (BR)

Economic evaluations, addiction interventions, 1647–1659
Ecstasy *see* MDMA
Editors
authors, ethics, 1–2 (E)
networking, Quebec, 3–4 (E)
Education
cannabis, youths, 685–692, 1681–1692
Egypt, drug dependence, 707 (N & N)
Eighteenth century
gin craze, 375 (BR)
modern relevance, 139–140 (E)
Elderly people, alcohol, 546–547 (BR)
Electronic gaming machines, 53–60
EMCDDA *see* European Monitoring Centre for Drugs and Drug Addiction
Ephedrine, methamphetamine, precursor regulation, 1229–1237
Ethanol, pharmacokinetics, metabolites, 73–80 (S2)
Ether, 1167–1168
Ethics
addiction, neuroscience, 867–870 (E), 871–874 (C)
authors, editors, 1–2 (E)
Ethnicity
alcohol, tobacco, substance misuse, 225–234
bupropion, menthol, smoking, 1387–1393
cocaine, 1705–1711
culture, smoking, 139–145 (S1)
drug dependence, stress, 305–315
stress, drug dependence, 305–315
Ethyl glucuronide, 51–61 (S2)
Europe
advertising, tobacco, 383 (N & N)
alcohol, drinking patterns, 1007–1008 (BR)
College of Addictions, 862 (N & N)
tobacco, advertising, 383 (N & N)
European Monitoring Centre for Drugs and Drug Addiction, 383 (N & N)
European Union, Norway, drug use, 471–485
Exartisis, 253 (E)
Exercise, smoking, cessation, 523–532
Expectancy
arousal, video lottery, gambling, 733–738
drinking patterns, gender, sexual behavior, 1069–1075
video lottery, gambling, arousal, 733–738
Exposure, drugs, children, 1615–1623
Eye movements, smoking, attentional bias, 825–836

Families, collaborative approach, 5–6 (C)
Family
craving, history, smoking, stress, 657–664
friends, smoking, 923–931
influences, smoking, youths, 1–20 (S1), 21–36 (S1)
stress, craving, history, smoking, 657–664
tobacco, youths, 815–824
Fetal alcohol syndrome, pregnancy, drinking patterns, 1513–1520
Finland
alcohol, 1468 (N & N)
control, 1173–1174 (BR)
media, 281–290
passive smoking, tobacco, workplace, 1111–1117
5-hydroxytryptophol, biological markers, 63–72 (S2)
France
cessation
gender, smoking, 1575–1583
smoking, 1468 (N & N)
Friends, family, smoking, 923–931
Fuller, Richard, 1485–1492 (I)
Functions, polydrug use, 951–963
Fuzzy set reliability, 1239–1247

Gambling
addiction theory, 709 (E)
addictive behavior, automaticity, attentional bias, 61–70
arousal, expectancy, video lottery, 733–738
diagnosis, impulse control disorders, 1661–1672, 1673–1679 (C)
electronic gaming machines, 53–60
Netherlands, 725–731
prevalence, Netherlands, scratchcards, 725–731
treatment, 130–131 (BR)
types of gamblers, treatment, 645–655
Gamma-hydroxybutyrate, overdose, Australia, 199–204
Gender
alcohol
drinking patterns, myocardial infarction, 1453–1468
ethnicity, tobacco, substance misuse, 225–234
cessation, France, smoking, 1575–1583
difference, heritability, smoking behavior, 23–31
drinking patterns
expectancy, sexual behavior, 1069–1075
myocardial infarction, alcohol, 1453–1468
ethnicity, alcohol, tobacco, substance misuse, 225–234

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

France, smoking, cessation, 1575–1583
heritability, smoking behavior, difference, 23–31
General practice, illicit drugs, Scotland, 119–126
General surgery, alcohol, mortality, 611–616
Genetics, smoking, tobacco, youths, 1087–1100
GHB *see* gamma-hydroxybutyrate
Gin craze, 18th century, 375 (BR)
Group therapy, substance misuse, 1009–1010

Hair analysis, substance misuse, epidemiology, 987–994
Harm reduction, heroin, 83–91
Health service utilization, heroin, benzodiazepine, 1129–1135
Heritability, smoking behavior, gender difference, 23–31
Heroin, 130 (BR), 1464 (L)
administration route, HIV, 749–760
availability
harm reduction, injecting drug use, 83–91
injecting drug use, 93–95
benzodiazepine, health service utilization, 1129–1135
detoxification, treatment outcomes, 453–462
consent, 1775–1776
therapy, 1634–1635 (L)
drug-related deaths
methadone, 387–388 (E), 419–425
morphine, 6-monoacetylmorphine, 463–470
6-monoacetylmorphine, morphine, 463–470
harm reduction, 83–91
HIV, administration route, 749–760
injecting drug use
availability, 93–95
harm reduction, 83–91
Vietnam, 1053–1060
prevalence, 413–418
morphine, 6-monoacetylmorphine, drug-related deaths, 463–470
Netherlands, prescription, 247–249 (E)
overdose, 1169–1171, 1171, 1171–1172 (L)
prescription, Netherlands, 247–249 (E)
6-monoacetylmorphine, drug-related deaths, morphine, 463–470
therapy, consent, 1634–1635 (L)
Vietnam, injecting drug use, 1053–1060
UK, 547 (BR)
History of medicine, Alexander the Great, alcohol, 561–567
HIV
administration route, heroin, 749–760
injecting drug use, needle sharing, southern Thailand, 1153–1161
prisons, syringe exchange programs, 153–158
HIV/AIDS, Amsterdam Cohort Studies, 246 (N & N)
Hong Kong, alcohol consumption, 215–224
Hypnotic dependence, zolpidem, zopiclone, drug use, 1371–1378

Ignition interlock, 13–19 (S2)
Iguana column, 550–551 (N & N)
Impaired control, gambling, 53–60
Impulse control disorders
gambling, diagnosis, 1661–1672, 1673–1679 (C)
India, inhalant abuse, 1169 (L)
Industry bias, *Regulatory Toxicology and Pharmacology*, 706 (N & N)
Inhalants
abuse, India, 1169 (L)
dependence, ether, 1167–1168
Injecting drug use
aging, marginality, 761–770
availability
harm reduction, heroin, 83–91
heroin, 93–95
blood-borne virus, 171–178
broken needles, risk, 1163–1166
buprenorophine, methadone, illicit drug use, 1585–1597
heroin, Vietnam, 1053–1060
HIV, southern Thailand, needle sharing, 1153–1161
illicit drug use, buprenorophine, methadone, 1585–1597
marginality, aging, 761–770
opiates, prisons, 1257–1265
Vietnam, heroin, 1053–1060
Injury
alcohol
drinking patterns, 1782–1783 (BR)
risk, 1209–1228
intervention, 43–52
meta-analysis, 1277–1286
Canada
drinking patterns, 865–866 (E)
mortality, 883–893
drinking patterns, 1483–1484 (E)
alcohol, 1782–1783 (BR)
risk, 1209–1228
illicit drugs, Olympic Games, 97–102
intervention, alcohol, 43–52
meta-analysis, alcohol, 1277–1286
Interdependencies among contexts, social context, 151–155 (S1)
International Conference on Gambling and Risk-taking, 1326 (N & N)
International control
cannabis, 141 (E)
League of Nations, 143–151
International treaty, tobacco control, 706 (N & N)
Intervention
alcohol, 1025–1026
injury, 43–52
mental health disorders, 1061–1068
primary care, 1447–1451
Intimate partner violence, 791–797
Intoxication
alcohol
licensed premises, 1287–1295
social consequences, 1021–1023 (E)
Ireland, smoking, workplace, 1777 (N & N)
Islam, wine, 376–377 (BR)
Israel Society for the Prevention of Alcoholism, 255–259
Italian Association on Addiction Psychiatry, 1039–1042

Kendell, Robert, 539–541 (O)
Kornetsky, Conan, 875–882 (I)

LAAM *see* levo-alpha acetylmethadol
League of Nations, cannabis, international control, 143–151
Lebanon, tobacco use, university students, 933–939
Levo-alpha acetylmethadol, methadone, primary care, 1605–1613
Licensed premises, 1287–1295
Literature, drugs, 1784 (BR)
Liver cirrhosis, Canada, 1267–1276
Liver function tests, biological markers, 31–43 (S2)
Lofexidine, 427–439

Major depression, substance misuse, treatment outcomes, 499–508
Management, behavioral techniques, addiction, 378–379 (BR)
Marginality, injecting drug use, aging, 761–770
Marketing, Addict, 136 (N & N), 550 (N & N)
Mass media, smoking, youths, 79–103 (S1)
Master class, addiction research, 383–284 (N & N)
Maternal drug use, neonatal intensive care, neonatal abstinence syndrome, 785–789

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

MDMA
death, moclobemide, 365–368
Media, alcohol, Finland, 281–290
Medicinal specifics, addiction cures, USA, 261–267
Megadose lorazepam dependence, 1635–1636 (L)
Memory
cannabis, MDMA, 1003–1004 (L)
polydrug use, psychostimulant use, 1004–1005 (L)
Mental health disorders, alcohol, intervention, 1061–1068
Menthol, smoking, 1387–1393
Meta-analysis, alcohol, injury, 1277–1286
Metabolites, ethanol, 73–80 (S2)
Metamphetamine, precursor regulation, 1229–1237
Methadone
Australia, 385–386 (E)
buprenorphine, 1633–1634 (L)
illicit drug use, injecting drug use, 1585–1597
opiates, treatment outcomes, 441–452
quality of life, 693–702
Scotland, drug-related deaths, 995–1002
Methamphetamine, precursor regulation, 1463–1464 (L)
Mind-acting substances, 1027 (E)
Moclobemide, death, MDMA, 365–368
Modern relevance, 18th century, public health crisis, 139–140 (E)
Moist oral snuff, smoking, cessation, reduction, Sweden, 1183–1189, 1191–1195, 1197–1207
Morphine, 6-monoacetylmorphine, drug-related deaths, heroin, 463–470
Mortality
alcohol
Canada, liver cirrhosis, 1267–1276
general surgery, 611–616
Myocardial infarction, alcohol, 1453–1468

NAS *see* neonatal abstinence syndrome
National Institute on Drug Abuse, 136 (N & N)
National Treatment Outcome Research Study, 291–303
Natural recovery, alcohol dependence, 1727–1746
Naxalone, 427–439
Needle sharing, HIV, southern Thailand, 1153–1161
Needs-based targeting, cigarette design, 1547–1561
Neighborhood, ethnicity, cocaine, crack, 1705–1711
Neonatal abstinence syndrome
buprenorphine
conception, pregnancy, 103–110
treatment outcomes, 1599–1604
maternal drug use, neonatal intensive care, 785–789
Nepal, alcohol dependence, 339–343
Netherlands
heroin prescription, 247–249 (E)
gambling, scratchcards, 725–731
Networking, editors, Quebec, 3–4 (E)
Neuroscience
addiction, ethics, 867–870 (E), 871–874 (C)
Nicotine deprivation, 913–921
Nicotine gum
cessation
reduction, smoking, 1395–1402
smoking, 1747–1753
Nicotine patches, 1403–1407
Nicotine replacement therapy, 941–950
NIDA *see* National Institute on Drug Abuse
Nineteenth century, temperance, 857–858 (BR)
Nordic, alcohol research, 245–246 (N & N)
Norway, 471–485
NTORS *see* National Treatment Outcome Research Study

Olympic Games, 97–102
Opiates
addiction, 1638–1639 (BR)
buprenorphine, 132 (BR)
buprenorphine
addiction, 132 (BR)
methadone, treatment outcomes, 441–452
drug-related deaths
overdose, substance misuse, 191–197
injecting drug use, prisons, 1257–1265
methadone, treatment outcomes, buprenorphine, 441–452
Overdose
Australia, gamma-hydroxybutyrate, 199–204
drug-related deaths, opiates, 191–197
gamma-hydroxybutyrate, Australia, 199–204
heroin, 1169–1171, 1171, 1171–1172 (L)
opiates, substance misuse, drug-related deaths, 191–197
polydrug use, 711 (E)

Parents
cessation, children, smoking, 585–593, 595–599 (C)
Passive smoking, Finland, 1111–1117
Patient-centered approach, 859–860 (BR)
Payees, disability, welfare, drug use, 965–975
Peers, smoking, youths, 37–55 (S1)
Pharmacotherapy, tiagabine, cocaine, methadone, 1625–1632
Pharmacy, drug use, Delphi study, 487–497
Physician's inquiries, drinking patterns, alcohol use, 895–900
Physician's opinions, treatment outcomes, alcohol dependence, 617–626
Policy research, alcohol, 1341 (E)
Political economy, tobacco control, smoking, youths, 123–138 (S1)
Politics, alcohol dependence, 1781–1782 (BR)
Polydrug use
cocaine, heroin, 7–22
functions, youths, 951–963
heroin, cocaine, 7–22
memory, psychostimulant use, 1004–1005 (L)
overdose, 711 (E)
Precursor regulation, 1177–1179 (E)
Pregnancy
buprenorphine, 103–110
drinking patterns, fetal alcohol syndrome, 1513–1520
self-report, smoking, 1315–1320
Primary care
alcohol, intervention, 1447–1451
detoxification program, substance misuse, 509–516
intervention, alcohol, 1447–1451
levo-alpha acetylmethadol, methadone, 1605–1613
methadone, levo-alpha acetylmethadol, 1605–1613
Primary prevention, alcohol, youths, 397–411
Prisons
attitudes, substance misuse, 179–184
benzodiazepine, prevalence, 1427–1432
HIV, syringe exchange programs, 153–158
injecting drug use, opiates, 1257–1265
syringe exchange programs, HIV, 153–158
Prospective cohort study, treatment outcomes, National Treatment Outcome Research Study, 291–303
Psychiatric disorders, dual diagnosis, 131–132 (BR)
Psychiatric inpatients, substance misuse disorders, 111–118
Psychometric assessment
blood-borne virus, injecting drug use, 171–178

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

psychiatric inpatients, substance misuse disorders, 111–118
Psychostimulant use, memory, 1004–1005 (L)
Public health
crisis, 18th century, 139–140 (E)
illicit drugs, Olympic Games, 97–102

Quality of life, buprenorphine, methadone, 693–702
Québec
alcohol consumption, drinking patterns, 205–213
editors, networking, 3–4 (E)
Questionnaire development, benzodiazepine, craving, 1143–1152

Recovery
addiction, 1783–1784 (BR)
substance misuse, 545 (BR)

Recreation, tourism, 1713–1721
Regulatory Toxicology and Pharmacology, industry bias, 706 (N & N)
Relapse, alcohol dependence, 706–707 (N & N)
Release from prison, Scotland, drug-related deaths, 185–190
Reliability
craving, smoking, tobacco, 1537–1546
retrospective data, smoking, 1307–1313
Research
alcohol, drugs, 1641–1643 (E)
alcohol industry, 1773–1774 (L)
Retention, treatment outcomes, 673–684
Retrospective data, reliability, smoking, 1307–1313
Rexed, Bror, 127–128 (O)
Risk
alcohol, drinking patterns, injury, 1209–1228
broken needles, injecting drug use, 1163–1166
clubs, drugs, prevalence, 1693–1703
illicit drugs, prevalence, women, 1419–1426
prevalence
clubs, drugs, 1693–1703
women, illicit drugs, prevalence, 1419–1426
Russia, alcohol consumption, 369–370 (L), 549–550 (N & N)

Scientific literature, South America, 1335–1336 (N & N)
Scotland
Clinical Addictions Research Group, 1014–1015 (N & N)
drug-related deaths
methadone, 995–1002
release from prison, 185–190
general practice, illicit drugs, 119–126
methadone, drug-related deaths, 995–1002
release from prison, drug-related deaths, 185–190
Scratchcards, Netherlands, 725–731
Self-report
alcohol dependence, iii–iv (S2)
collaterals, drinking patterns, 21–29 (S2)
drinking patterns
validity, 1–12 (S2)
drug use, fuzzy set reliability, 1239–1247
pregnancy, smoking, 1315–1320
Sexual behavior, drinking patterns, 1069–1075
Sexually transmitted infections, 159–169
SIPDip *see* Italian Association on Addiction Psychiatry
Smokeless tobacco use, USA, 1077–1085
Smoking
alcohol consumption, 355–363
alcohol dependence, tobacco, 805–814
attentional bias
craving, 1409–1417
eye movements, 825–836
behavior, gender difference, heritability, 23–31
bupropion, menthol, ethnicity, 1387–1393
cessation
children, parents, 585–593, 595–599 (C)
constipation, 1563–1567
exercise, 523–532
France, 1468 (N & N)
gender, 1575–1583
moist oral snuff, reduction, Sweden, 1183–1189, 1191–1195, 1197–1207
nicotine gum, 1747–1753
reduction, 1395–1402
nicotine patches, oral selegiline, 1403–1407
cigarettes
design, 1547–1561
prices, 105–122 (S1), 147–149 (S1)
craving
attentional bias, 1409–1417
family history, stress, 657–664
reliability, tobacco, 1537–1546
culture, ethnicity, youths, 139–145 (S1)
damage, tobacco, 129–130 (BR)
ethnicity
bupropion, menthol, 1387–1393
exercise, cessation, 523–532
eye movements, attentional bias, 825–836
family
craving, history, stress, 657–664
friends, 923–931
influences, youths, 1–20 (S1), 21–36 (S1)
France
cessation, 1468 (N & N)
gender, 1575–1583
friends, family, 923–931
gender
behavior, difference, heritability, 23–31
genetics, 1087–1100
heritability, 23–31
Ireland, workplace, 1777 (N & N)
mass media, youths, 79–103 (S1)
menthol, ethnicity, bupropion, 1387–1393
moist oral snuff, cessation, reduction, Sweden, 1183–1189, 1191–1195, 1197–1207
needs-based targeting, cigarette design, 1547–1561
nicotine gum
cessation, 1747–1753
reduction, 1395–1402
nicotine patches, cessation, oral selegiline, 1403–1407
nicotine replacement therapy, tobacco use, 941–950
oral selegiline, nicotine patches, cessation, 1403–1407
parents, children, cessation, 585–593, 595–599 (C)
peers, youths, 37–55 (S1)
political economy, tobacco control, youths, 123–138 (S1)
pregnancy, self-report, 1315–1320
prevalence
cessation, reduction, 1101–1110
UK, 1569–1574
reliability
craving, tobacco, 1537–1546
retrospective data, 1307–1313
self-report, pregnancy, 1315–1320
smokeless tobacco use, USA, 1077–1085
Sweden, moist oral snuff, cessation, reduction, 1183–1189, 1191–1195, 1197–1207
USA, tobacco, smokeless tobacco use, 1077–1085
workplace, Ireland, 1777 (N & N)
youths, iii–iv (S1)
cigarette prices, tobacco control, 105–122 (S1), 147–149 (S1)

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

community, 57–77 (S1)
culture, ethnicity, 139–145 (S1)
genetics, tobacco, 1087–1100
influences, 1–20 (S1), 21–36 (S1)
mass media, 79–103 (S1)
peers, 37–55 (S1)
political economy, tobacco control, 123–138 (S1)
status, 1765–1772
tobacco, genetics, 1087–1100
tobacco control
cigarette prices, 105–122 (S1), 147–149 (S1)
Snus see moist oral snuff
Social capital, natural recovery, alcohol dependence, 1727–1746
Social consequences, alcohol, intoxication, 1021–1023 (E)
Social context
aggression, alcohol, drinking patterns, 33–42
interdependencies among contexts, 151–155 (S1)
Social use, alcohol, cannabis, attentional bias, 235–244
Society for the Study of Addiction, 246
Socioeconomic status
drinking patterns, 559 (E)
youths, 601–610
smoking, youths, 1765–1772
South America, scientific literature, 1335–1336 (N & N)
Southern Thailand, injecting drug use, needle sharing, HIV, 1153–1161
Spain, drug abuse, 861 (N & N)
Spit tobacco, systematic review, chewing tobacco, 569–583
Sport, youths, drug use, 1249–1256
Stress
craving, family history, smoking, 657–664
drug dependence, ethnicity, 305–315
family history, smoking, craving, 657–664
gender, smoking, 847–855
family history, craving, 657–664
gender, 847–855
Substance misuse disorders, psychiatric inpatients, psychometric assessment, 111–118
Sweat patches, cocaine, 317–324
Sweden, moist oral snuff, smoking, 1183–1189, 1191–1195, 1197–1207
Switzerland, drinking patterns, 1433–1446, 1774–1775 (L)
Syringe exchange programs, prisons, 153–158
Systematic review, chewing tobacco, 569–583

Temperance, nineteenth century, 857–858 (BR)
Tiagabine, cocaine, methadone, pharmacotherapy, 1625–1632
Tobacco
advertising, Europe, 383 (N & N)
smoking, 805–814
cigar use, youths, drug delivery device, 1379–1386
craving, 1537–1546
damage, 129–130 (BR)
dependence, nicotine deprivation, alcohol dependence, 913–921
Europe, advertising, 383 (N & N)
Finland, workplace, passive smoking, 1111–1117
gender, ethnicity, alcohol, substance misuse, 225–234
genetics, smoking, youths, 1087–1100
Lebanon, use, university students, 933–939
nicotine replacement therapy, smoking, use, 941–950
reliability, craving, 1537–1546
smokeless tobacco use, USA, 1077–1085
structure, youths, 815–824
treatment, 136–137 (N & N)
USA, smoking, smokeless tobacco use, 1077–1085
women, 553–557 (E)
Tobacco control, 137 (N & N)
cigarette prices, smoking, youths, 105–122 (S1), 147–149 (S1)
international treaty, 706 (N & N)
political economy, smoking, youths, 123–138 (S1)
Tourism, drug use, recreation, 1713–1721
Transtheoretical model, smoking, cessation, 345–354, 837–846
Treatment facilities, audit, 1467 (N & N)
Treatment
addiction, 858–859 (BR)
alcohol, 1335 (N & N), 1637–1638 (BR)
cocaine dependence, dexamphetamine, 1137–1141
criminal justice system, substance misuse, 1119–1128
gambling, 130–131 (BR)
types of gamblers, 645–655
substance misuse, 1327–1328
criminal justice system, 1119–1128
tobacco, 136–137 (N & N)
Treatment outcomes
abstinence, alcohol dependence, 901–911
alcohol use disorders, long-term influence, 325–337

buprenorphine
detoxification, heroin, 453–462
methadone, opiates, 441–452
neonatal abstinence syndrome, 1599–1604
cannabis
heroin, methadone, 269–279
methadone, 251–252 (E), 1321–1323 (L)
heroin, 269–279
detoxification, heroin, buprenorphine, 453–462
drug use improvement, retention, 673–684
major depression, substance misuse, 499–508
methadone
buprenorphine, opiates, 441–452
cannabis, 251–252 (E), 1321–1323 (L)
heroin, 269–279
National Treatment Outcome Research Study, prospective cohort study, 291–303
neonatal abstinence syndrome, buprenorphine, 1599–1604
opiates, buprenorphine, methadone, 441–452
retention, drug use improvement, 673–684
substance misuse, major depression, 499–508

Uchtenhagen, Ambros, 389–396 (I)
UK
Alcohol Education and Research Council, 862 (N & N)
heroin, 547 (BR)
prevalence, smoking, 1569–1574
United Nations Office on Drugs and Crime, 1014 (N & N)
University students
alcohol consumption, prevention, 627–633
Lebanon, tobacco use, 933–939
USA
addiction cures, medicinal specifics, 261–267
black market, 1639 (BR)
drinking patterns, intimate partner violence, 791–797
drug control, 375–376 (BR)
smokeless tobacco use, 1077–1085

Vacation habits, addiction researcher, 245 (N & N)
Validity, self-report, drinking patterns, 1–12 (S2)
Video lottery, gambling, arousal, expectancy, 733–738
Vietnam, heroin, injecting drug use, 1053–1060
Violence, alcohol, 543–544 (BR)

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs

Volatile solvents
  mortality, 1467–1468 (N & N)
  substance misuse, youths, 771–784

Welfare, drug use, payees, disability, 965–975
WHO *see* World Health Organization
Wine, Islam, 376–377 (BR)
Withdrawal signs, ether, inhalant dependence, 1167–1168
Women
  illicit drugs, prevalence, risk, 1419–1426
  tobacco, 553–557 (E)
Workplace
  Finland, passive smoking, tobacco, 1111–1117
  Ireland, smoking, 1777 (N & N)
World Health Organization report, alcohol, 1343–1350, 1351–1370 (C)

Young researchers, award, 1778 (N & N)
Youths
  advertising awareness, alcohol, 1297–1306
  age-associated bias, cannabis dependence, 71–82
  alcohol, 1777 (N & N)
    primary prevention, 397–411
    tobacco, 1755–1763
  areca quid, 1723–1729
  Attitudes–Social Influence Self-efficacy model, areca quid, 1723–1729
  cannabis
    age-associated bias, 71–82
    education, 685–692, 1681–1692
  cigar use, drug delivery device, 1379–1386
  cigarette prices, 105–122 (S1), 147–149 (S1)
  community, smoking, 57–77 (S1)
  culture, ethnicity, smoking, 139–145 (S1)
  drinking patterns, 1505–1511
    socioeconomic status, 601–610
  drug use, sport, 1249–1256
  education, cannabis, 685–692, 1681–1692
  family influences, smoking, 1–20 (S1), 21–36 (S1)
  family structure, tobacco, 815–824
  functions, polydrug use, 951–963
  genetics, smoking, tobacco, 1087–1100
  mass media, smoking, 79–103 (S1)
  peers, smoking, 37–55 (S1)
  political economy, tobacco control, smoking, 123–138 (S1)
  primary prevention, alcohol, 397–411
    political economy, 123–138 (S1)
  socioeconomic status
    drinking patterns, 601–610
    smoking, 1765–1772
  sport, drug use, 1249–1256
  substance misuse, volatile solvents, 771–784
  tobacco control
    cigarette prices, 105–122 (S1), 147–149 (S1)
    political economy, 123–138 (S1)

Zolpidem, zopiclone, dependence, 1371–1378

© 2003 Society for the Study of Addiction to Alcohol and Other Drugs